CTRI/2012/10/003056已完成1 期
A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •During the first phase of recruitment (for DSMB review), no female subjects will be recruited.
- •Informed consent must be obtained from the subject prior to beginning any study specific procedures indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol.
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the administration of the study vaccine, or planned use during the study period.
- •Receipt of any other licensed influenza vaccines or investigational influenza vaccine within 6 months prior to enrollment in this study or expected receipt of any vaccination before the final immune response blood collection.
- •History of hypersensitivity to any component of inactivated influenza vaccines.
- •Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within six months prior to the administration of the study vaccine. The use of inhaled and nasal steroids will be permitted.
- •Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination.
- •Administration of immunoglobulin and/or any blood products within the three months preceding the administration of the study vaccine or during the study.
- •Acute illness of moderate or severe intensity at the time of enrollment, including any illness associated with fever >=100.5 0F.
- •Any cardiopulmonary disease, including asthma, requiring ongoing medical therapy; known or suspected abnormal hepatic or renal function, or any congenital abnormalities, including hemglobinopathies, which could increase the risk of influenza complications.
- •History of any neurological disorders or seizures (with the exception of febrile seizures during childhood) related to an underlying immune disease or disorder, such as but not limited to: multiple sclerosis, lupus, Guillain-Barre syndrome.
- •Any condition that in the opinion of the investigator would interfere with evaluation of the vaccine or interpretation of study results.
- •Females who are found positive in Urinary Pregnancy Test; Pregnant or lactating female, and; Females planning to become pregnant or planning to discontinue contraceptive precautions within 60 days of enrollment in this study.
- •Volunteers found positive in alcohol breath test and drugs of abuse test
研究者
相似试验
已完成
1 期
Influenza Vaccine StudyCTRI/2012/10/003080Cadila Pharmaceuticals Limited180
尚未招募
Unknown
A clinical study to evaluatethe efficacy of JUVECOL K for period of 16 weeks in improving Knee Joint HealthCTRI/2024/07/070176aturetech co Ltd
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 DiabetesMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2010-021057-39-BEovo Nordisk A/S21
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) and Adult Subjects with Type 2 DiabetesMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2010-021057-39-SIovo Nordisk A/S60
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients with Stage IIIb-IV Non-Small Cell Lung Cancer (NSCLC) - NExUSon small cell lung cancerMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-002688-26-ITBAYER990